Protective role of butyrate in obesity and diabetes: New insights

Mayorga-Ramos, Arianna; Barba-Ostria, Carlos; Simancas‐Racines, Daniel; Guamán, Linda P.

doi:10.3389/fnut.2022.1067647

Cited by 33 publications

(22 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This includes its utilization in the treatment of hemoglobinopathies; colorectal cancer; gastrointestinal diseases; and metabolic disorders, including obesity [56][57][58]. It is regarded as a safe drug, with therapeutic doses ranging from 150 to 300 mg, and in some cases up to 2000 mg/day, with no demonstrated adverse reactions or clinical side effects [59]. Previously, butanoic acid has been reported to exert anti-obesity properties by improving fasting glycemia, reducing body weight, enhancing insulin tolerance, and improving energy metabolism in animal models [60].…”

Section: Discussionmentioning

confidence: 99%

Anti-Obesity Effects of Marine Macroalgae Extract Caulerpa lentillifera in a Caenorhabditis elegans Model

Chumphoochai,

Manohong,

Niamnont

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Obesity is a multifactorial disease characterized by an excessive accumulation of fat, which in turn poses a significant risk to health. Bioactive compounds obtained from macroalgae have demonstrated their efficacy in combating obesity in various animal models. The green macroalgae Caulerpa lentillifera (CL) contains numerous active constituents. Hence, in the present study, we aimed to elucidate the beneficial anti-obesity effects of extracts derived from C. lentillifera using a Caenorhabditis elegans obesity model. The ethanol (CLET) and ethyl acetate (CLEA) extracts caused a significant decrease in fat consumption, reaching up to approximately 50–60%. Triglyceride levels in 50 mM glucose-fed worms were significantly reduced by approximately 200%. The GFP-labeled dhs-3, a marker for lipid droplets, exhibited a significant reduction in its level to approximately 30%. Furthermore, the level of intracellular ROS displayed a significant decrease of 18.26 to 23.91% in high-glucose-fed worms treated with CL extracts, while their lifespan remained unchanged. Additionally, the mRNA expression of genes associated with lipogenesis, such as sbp-1, showed a significant down-regulation following treatment with CL extracts. This finding was supported by a significant decrease (at 16.22–18.29%) in GFP-labeled sbp-1 gene expression. These results suggest that C. lentillifera extracts may facilitate a reduction in total fat accumulation induced by glucose through sbp-1 pathways. In summary, this study highlights the anti-obesity potential of compounds derived from C. lentillifera extracts in a C. elegans model of obesity, mediated by the suppression of lipogenesis pathways.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Obesity Effects of Marine Macroalgae Extract Caulerpa lentillifera in a Caenorhabditis elegans Model

Chumphoochai,

Manohong,

Niamnont

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

show abstract

“… 33 Meanwhile, SCFAs also have a regulatory differentiation effect on immune cells such as macrophages, perhaps by influencing the secretion of some cytokines such as interleukin-12(IL-12), IL-6, CO. 34 In terms of energy metabolism, both propionate and butyrate can increase intestinal glucose production. 35 Propionate mainly affects glucose and lipogenesis in liver indirectly, while butyrate can directly upregulate intestinal glucogenesis genes. 36 In addition, SCFAs also participate in the gut-brain axis to affect the production of hormones to regulate metabolic activity.…”

Section: Dysbiosis Of Gastrointestinal Microbiome Is An Important Par...mentioning

confidence: 99%

Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus

Zhou,

Chen,

Cai

et al. 2024

DMSO

View full text Add to dashboard Cite

Purpose of Review The aim of this review is to summarize the role of gastrointestinal microbiome (GM) in the development of type 2 diabetes mellitus (T2DM). Besides, we discuss the feasibility of applying FMT in the treatment of T2DM and propose a series of processes to refine the use of FMT in the treatment of T2DM. Recent Findings T2DM is a metabolic disease which is connected with the GM. According to many researches, GM can produce a variety of metabolites such as bile acid, short chain fatty acids, lipopolysaccharides and trimethylamine oxide which play an important role in metabolism. FMT is a method to regulate GM and has been observed to be effective in the treatment of metabolic diseases such as T2DM in some mouse models and people. However, there is still a lack of direct evidence for the use of FMT in the treatment of T2DM, and the process of FMT is not standardized. Summary Dysregulation of GM is closely related to the development of T2DM. Promoting the conversion of GM in T2DM patients to normal population through FMT can reduce insulin resistance and lower their blood glucose level, which is an optional treatment for T2DM patients in the future. At present, the feasibility and limitations of applying FMT to the treatment of T2DM need to be further studied.

show abstract

“…Another relevant metabolite is butyrate, a natural byproduct of dietary fiber fermentation in the colon. In addition to being the gut’s primary source of energy, butyrate has several immunomodulatory and metabolic functions throughout the body [ 65 , 66 , 67 ]. Moreover, butyrate may exert neuroprotective effects, as its supplementation in a motor neuron-like cell model of ALS significantly restored mitochondrial respiratory capacity and biogenesis [ 68 ].…”

Section: Gut Dysbiosis Contributes To Pathology In Amyotrophic Latera...mentioning

confidence: 99%

Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives

Noor Eddin,

Alfuwais,

Noor Eddin

et al. 2024

Nutrients

View full text Add to dashboard Cite

Amyotrophic Lateral Sclerosis (ALS) is a highly fatal neurodegenerative disorder characterized by the progressive wasting and paralysis of voluntary muscle. Despite extensive research, the etiology of ALS remains elusive, and effective treatment options are limited. However, recent evidence implicates gut dysbiosis and gut–brain axis (GBA) dysfunction in ALS pathogenesis. Alterations to the composition and diversity of microbial communities within the gut flora have been consistently observed in ALS patients. These changes are often correlated with disease progression and patient outcome, suggesting that GBA modulation may have therapeutic potential. Indeed, targeting the gut microbiota has been shown to be neuroprotective in several animal models, alleviating motor symptoms and mitigating disease progression. However, the translation of these findings to human patients is challenging due to the complexity of ALS pathology and the varying diversity of gut microbiota. This review comprehensively summarizes the current literature on ALS-related gut dysbiosis, focusing on the implications of GBA dysfunction. It delineates three main mechanisms by which dysbiosis contributes to ALS pathology: compromised intestinal barrier integrity, metabolic dysfunction, and immune dysregulation. It also examines preclinical evidence on the therapeutic potential of gut-microbiota-modulating agents (categorized as prebiotics, probiotics, and postbiotics) in ALS.

show abstract

Protective role of butyrate in obesity and diabetes: New insights

Cited by 33 publications

References 91 publications

Anti-Obesity Effects of Marine Macroalgae Extract Caulerpa lentillifera in a Caenorhabditis elegans Model

Anti-Obesity Effects of Marine Macroalgae Extract Caulerpa lentillifera in a Caenorhabditis elegans Model

Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus

Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives

Contact Info

Product

Resources

About